(Q37299181)

English

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

scientific article published on 29 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

1

object named as

Antoni Ribas

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

John M Kirkwood

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Michael B Atkins

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Theresa L Whiteside

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

William Gooding

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Andreas Kovar

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Stephen D Gillies

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Oscar Kashala

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Michael A Morse

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

29 July 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

68

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Intratumoral immunocytokine treatment results in enhanced antitumor effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

Interleukin-2-dependent mechanisms of tolerance and immunity in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

Cytokine-based therapy and biochemotherapy for advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

Management of cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

6 September 2017

IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

14 September 2017

Immunocytokines: a new approach to immunotherapy of melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

26 June 2018

Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

26 June 2018

Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

2 September 2018

Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

2 September 2018

Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2724499

2 September 2018

Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/19640287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of the density of cell surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA

1 reference

https://pubmed.ncbi.nlm.nih.gov/19640287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination

1 reference

https://pubmed.ncbi.nlm.nih.gov/19640287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19640287

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-7-68

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37299181&oldid=2200141761"